These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 32950419)

  • 1. Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD: The ASET Pilot Study.
    Kogame N; Guimarães PO; Modolo R; De Martino F; Tinoco J; Ribeiro EE; Kawashima H; Ono M; Hara H; Wang R; Cavalcante R; Moulin B; Falcão BAA; Leite RS; de Almeida Sampaio FB; Morais GR; Meireles GC; Campos CM; Onuma Y; Serruys PW; Lemos PA
    JACC Cardiovasc Interv; 2020 Oct; 13(19):2251-2262. PubMed ID: 32950419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prasugrel Monotherapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Platinum-Chromium Everolimus Eluting Stent for Japanese Patients With Chronic Coronary Syndrome (ASET-JAPAN).
    Muramatsu T; Masuda S; Kotoku N; Kozuma K; Kawashima H; Ishibashi Y; Nakazawa G; Takahashi K; Okamura T; Miyazaki Y; Tateishi H; Nakamura M; Kogame N; Asano T; Nakatani S; Morino Y; Katagiri Y; Ninomiya K; Kageyama S; Takahashi H; Garg S; Tu S; Tanabe K; Ozaki Y; Serruys PW; Onuma Y
    Circ J; 2023 May; 87(6):857-865. PubMed ID: 36908118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary Intervention.
    Yamamoto K; Natsuaki M; Watanabe H; Morimoto T; Obayashi Y; Nishikawa R; Ando K; Suwa S; Isawa T; Takenaka H; Ishikawa T; Tamura T; Kawahatsu K; Hayashi F; Akao M; Serikawa T; Mori H; Kawamura T; Hagikura A; Shibata N; Ono K; Kimura T;
    JACC Cardiovasc Interv; 2024 May; 17(9):1119-1130. PubMed ID: 38749592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-dose prasugrel monotherapy without aspirin after PCI with the SYNERGY stent in East Asian patients presenting with chronic coronary syndromes or non-ST-elevation acute coronary syndromes: rationale and design of the ASET Japan pilot study.
    Masuda S; Muramatsu T; Ishibashi Y; Kozuma K; Tanabe K; Nakatani S; Kogame N; Nakamura M; Asano T; Okamura T; Miyazaki Y; Tateishi H; Ozaki Y; Nakazawa G; Morino Y; Katagiri Y; Garg S; Hara H; Ono M; Kawashima H; Lemos PA; Serruys PW; Onuma Y
    AsiaIntervention; 2023 Mar; 9(1):39-48. PubMed ID: 36936091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel Monotherapy After Percutaneous Coronary Intervention for Chronic Coronary Syndrome: Insights From ASET Pilot Studies.
    Masuda S; Tanabe K; Guimarães PO; Muramatsu T; Ozaki Y; De Martino F; Kozuma K; Garg S; Kotoku N; Ninomiya K; Kageyama S; Lemos PA; Onuma Y; Serruys PW
    JACC Asia; 2024 Mar; 4(3):171-182. PubMed ID: 38463674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry.
    Ishida M; Takahashi F; Goto I; Niiyama M; Saitoh H; Sakamoto T; Maegawa Y; Osaki T; Nishiyama O; Endo H; Sakamoto R; Kojima T; Koeda Y; Kimura T; Itoh T; Morino Y;
    Cardiovasc Interv Ther; 2020 Oct; 35(4):398-404. PubMed ID: 32776221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial.
    Natsuaki M; Watanabe H; Morimoto T; Yamamoto K; Obayashi Y; Nishikawa R; Ando K; Domei T; Suwa S; Ogita M; Isawa T; Takenaka H; Yamamoto T; Ishikawa T; Hisauchi I; Wakabayashi K; Onishi Y; Hibi K; Kawai K; Yoshida R; Suzuki H; Nakazawa G; Kusuyama T; Morishima I; Ono K; Kimura T
    Circulation; 2024 Feb; 149(8):585-600. PubMed ID: 37994553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
    Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
    JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of dual antiplatelet therapy with adjusted-dose prasugrel on mid-term vascular response in patients undergoing elective percutaneous coronary intervention with everolimus-eluting stents.
    Toba T; Shinke T; Otake H; Sugizaki Y; Takeshige R; Onishi H; Nagasawa A; Tsukiyama Y; Yanaka K; Nagano Y; Yamamoto H; Kawamori H; Matsuura A; Ishihara T; Matsumoto D; Igarashi N; Hayashi T; Yasaka Y; Kadotani M; Fujii T; Shite J; Okada M; Sakakibara T; Hirata KI
    Heart Vessels; 2019 Jun; 34(6):936-947. PubMed ID: 30599059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy After Polymer-Free Drug-Coated Stent Implantation: One-Month DAPT Trial.
    Hong SJ; Kim JS; Hong SJ; Lim DS; Lee SY; Yun KH; Park JK; Kang WC; Kim YH; Yoon HJ; Won H; Nam CM; Ahn CM; Kim BK; Ko YG; Choi D; Jang Y; Hong MK;
    JACC Cardiovasc Interv; 2021 Aug; 14(16):1801-1811. PubMed ID: 34332946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study.
    van der Sangen NMR; Claessen BEPM; Küçük IT; den Hartog AW; Baan J; Beijk MAM; Delewi R; van de Hoef TP; Knaapen P; Lemkes JS; Marques KM; Nap A; Verouden NJW; Vis MM; de Winter RJ; Kikkert WJ; Appelman Y; Henriques JPS
    EuroIntervention; 2023 May; 19(1):63-72. PubMed ID: 36734020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial.
    Lee H; Koo BK; Park KW; Shin ES; Lim SW; Rha SW; Bae JW; Jeon DW; Oh SK; Hur SH; Kim BS; Lee JH; Park TH; Lee NH; Kim HS;
    Am Heart J; 2017 Mar; 185():17-25. PubMed ID: 28267471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the Antithrombotic Effects of Prasugrel on Mid-Term Vascular Healing in Acute Coronary Syndrome vs. Stable Coronary Artery Disease.
    Toba T; Shinke T; Otake H; Kawamori H; Matsukawa N; Matsuura A; Ishihara T; Matsumoto D; Igarashi N; Hayashi T; Yasaka Y; Kadotani M; Fujii T; Shite J; Okada M; Sakakibara T; Hirata KI
    Circ J; 2021 May; 85(6):808-816. PubMed ID: 33431718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease-2.
    Kaul U; Arambam P; Sinha SK; Abhaichand R; Parida AK; Banker D; Mody R; Khan A; Sharma R; Moorthy N; Chandra S; Koduganti SC; Garg R; Sarma PR; Agrawal DK; Reddy KMK; Bangalore S
    Am Heart J; 2023 Feb; 256():128-138. PubMed ID: 36780372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P2Y
    Lee SY; Jeong YH; Yun KH; Cho JY; Gorog DA; Angiolillo DJ; Kim JW; Jang Y
    JACC Cardiovasc Interv; 2023 Aug; 16(15):1845-1855. PubMed ID: 37587591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.
    Mauri L; Kereiakes DJ; Normand SL; Wiviott SD; Cohen DJ; Holmes DR; Bangalore S; Cutlip DE; Pencina M; Massaro JM
    Am Heart J; 2010 Dec; 160(6):1035-41, 1041.e1. PubMed ID: 21146655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial.
    Guimarães PO; Franken M; Tavares CAM; Silveira FS; Antunes MO; Bergo RR; Joaquim RM; Hirai JCS; Andrade PB; Pitta FG; Mariani J; Nascimento BR; de Paula JET; Silveira MS; Costa TAO; Dall'Orto FTC; Serpa RG; Sampaio FBA; Ohe LN; Mangione FM; Furtado RHM; Sarmento-Leite R; Monfardini F; Assis SRL; Nicolau JC; Sposito AC; Lopes RD; Onuma Y; Valgimigli M; Angiolillo DJ; Serruys PW; Berwanger O; Bacal F; Lemos PA
    EuroIntervention; 2023 Jul; 19(4):e323-e329. PubMed ID: 37306039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
    Gilard M; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berland J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Endresen K; Benamer H; Kiss RG; Ungi I; Boschat J; Morice MC
    J Am Coll Cardiol; 2015 Mar; 65(8):777-786. PubMed ID: 25461690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.